Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

(2012) Jacqueline Detert et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

(2012) Monika Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Indirect Treatment Comparison of Abatacept with Methotrexate Versus Other Biologic Agents for Active Rheumatoid Arthritis Despite Methotrexate Therapy in the United Kingdom

(2012) P. GUYOT et al.   JOURNAL OF RHEUMATOLOGY

Phase II dose–response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate

(2012) Tsutomu Takeuchi et al.   Modern Rheumatology

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

(2012) M. E. Weinblatt et al.   RHEUMATOLOGY

A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach

(2011) Susanne Schmitz et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study

(2011) Yoshiya Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

A Dose–Response Meta-Analysis for Quantifying Relative Efficacy of Biologics in Rheumatoid Arthritis

(2011) J W Mandema et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Mortality Risk by Functional Status and Health-related Quality of Life in Patients with Rheumatoid Arthritis

(2011) K. MICHAUD et al.   JOURNAL OF RHEUMATOLOGY

Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

(2011) Patricia Guyot et al.   ARTHRITIS RESEARCH & THERAPY

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study

(2010) E. Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach

(2010) Emily Beth Devine et al.   PHARMACOTHERAPY

Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate

(2010) William Rigby et al.   ARTHRITIS CARE & RESEARCH

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

(2009) R Westhovens et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

(2009) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

(2009) J. A. Singh et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis

(2009) Der-Yuan Chen et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

(2009) Josef S Smolen et al.   LANCET

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy

(2008) E. Keystone et al.   ARTHRITIS AND RHEUMATISM

Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis

(2008) Victoria Bejarano et al.   ARTHRITIS AND RHEUMATISM

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

(2008) Edward Keystone et al.   ARTHRITIS AND RHEUMATISM

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

(2008) Paul Emery et al.   LANCET

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

(2008) Nobuyuki Miyasaka et al.   Modern Rheumatology